1. Home
  2. CNS vs MIRM Comparison

CNS vs MIRM Comparison

Compare CNS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNS
  • MIRM
  • Stock Information
  • Founded
  • CNS 1986
  • MIRM 2018
  • Country
  • CNS United States
  • MIRM United States
  • Employees
  • CNS N/A
  • MIRM N/A
  • Industry
  • CNS Investment Managers
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • CNS Finance
  • MIRM Health Care
  • Exchange
  • CNS Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • CNS 4.0B
  • MIRM 3.3B
  • IPO Year
  • CNS 2004
  • MIRM 2019
  • Fundamental
  • Price
  • CNS $76.27
  • MIRM $71.52
  • Analyst Decision
  • CNS Hold
  • MIRM Strong Buy
  • Analyst Count
  • CNS 3
  • MIRM 9
  • Target Price
  • CNS $82.00
  • MIRM $73.89
  • AVG Volume (30 Days)
  • CNS 207.2K
  • MIRM 751.2K
  • Earning Date
  • CNS 10-15-2025
  • MIRM 08-06-2025
  • Dividend Yield
  • CNS 3.26%
  • MIRM N/A
  • EPS Growth
  • CNS 23.33
  • MIRM N/A
  • EPS
  • CNS 3.15
  • MIRM N/A
  • Revenue
  • CNS $543,579,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • CNS $7.32
  • MIRM $36.76
  • Revenue Next Year
  • CNS $8.15
  • MIRM $17.48
  • P/E Ratio
  • CNS $24.19
  • MIRM N/A
  • Revenue Growth
  • CNS 11.54
  • MIRM 62.33
  • 52 Week Low
  • CNS $68.99
  • MIRM $36.86
  • 52 Week High
  • CNS $110.67
  • MIRM $71.74
  • Technical
  • Relative Strength Index (RSI)
  • CNS 54.20
  • MIRM 79.29
  • Support Level
  • CNS $71.31
  • MIRM $64.76
  • Resistance Level
  • CNS $75.51
  • MIRM $69.27
  • Average True Range (ATR)
  • CNS 1.97
  • MIRM 3.25
  • MACD
  • CNS 0.05
  • MIRM 0.86
  • Stochastic Oscillator
  • CNS 73.41
  • MIRM 97.43

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: